Opus Genetics presented positive clinical findings for its OPGx-BEST1 and OPGx-LCA5 gene therapy programs, showing improved retinal sensitivity and visual function. The company also announced that Phase 3 clinical trial dosing for OPGx-LCA5 is expected in Q4 2026, indicating significant progress in its drug development pipeline.
Opus Genetics (IRD) announced positive clinical findings from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina in Rio 2026. The OPGx-BEST1 program showed improved retinal sensitivity in 75% of evaluable participants in its Phase 1/2 trial, while OPGx-LCA5 demonstrated sustained improvements in visual acuity and light sensitivity in both adult and pediatric participants. This news is a significant positive catalyst for Opus Genetics as it validates their gene therapy platforms and de-risks future development. The announcement of Phase 3 clinical trial dosing for OPGx-LCA5 in Q4 2026 provides a clear timeline for a major milestone, which could lead to substantial long-term value creation if successful. For traders, this presents an opportunity for short-term upside due to increased investor confidence and long-term growth potential, though clinical trial risks always remain.